References
Kostkiewicz M, Olszowska M, Przewlocki T, Podolec P, Tracz W. Prognostic value of nitrate enhanced Tc99m MIBI SPECT study in detecting viable myocardium in patients with coronary artery disease. Int J Cardiovasc Imaging 19: 129–135.
Bonow RO. Identification of viable myocardium. Circulation 1996; 94: 2674–2680.
Auerbach MA, Schöder H, Gambhir SS, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99: 2921–2926.
Al-Mohammad A, Mahy IR, Norton MY, et al. Prevalence of hibernating myocardium in patients with severely impaired ischaemic left ventricles. Heart 1998; 80: 559–564.
Schinkel AFL, Bax JJ, Sozzi FB. Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. Heart 2002; 88: 125–130.
Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22: 221–236.
Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26: 142–186.
Kaul S. Myocardial contrast echocardiography: basic principles. Prog Cardiovasc Dis 2001; 44: 1–11.
Van der Wall EE, Bax JJ. Current clinical relevance of cardiovascular magnetic resonance and its relationship to nuclear cardiology. J Nucl Cardiol 1999; 6: 462–469.
Bonow RO, Dilsizian V. Thallium-201 and technetium-99m-sestamibi for assessing viable myocardium. J Nucl Med 1992; 33: 815–818.
Sciagra R, Pellegri M, Pupi A, et al. Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2000; 36: 739–745.
Bax JJ, Patton JA, Poldermans D, Elhendy A, Sandler MP. 18-Fluorodeoxyglucose imaging with PET and SPECT: Cardiac applications. Semin Nucl Med 2000; 30: 281–298.
Corbett J. Fatty acids for myocardial imaging. Semin Nucl Med 1999; 29: 237–258.
Gropler RJ, Geltman EM, Sampathkumaran K, et al. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography. J Am Coll Cardiol 1993; 22: 1587–1597.
Pohost GM. Is 31P-NMR spectroscopic imaging a viable approach to assess myocardial viability? Circulation 1995; 92: 9–10.
Williams MJ, Odabashian J, Laurer MS, Thomas JD, Marwick TH. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 27: 132–139.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39: 1151–1158.
Bonow RO. Myocardial viability and prognosis in patients with ischemic left ventricular dysfunction. J Am Coll Cardiol 2002; 39: 1159–1162.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bax, J.J., van der Wall, E.E. Evaluation of myocardial viability in chronic ischemic cardiomyopathy. Int J Cardiovasc Imaging 19, 137–140 (2003). https://doi.org/10.1023/A:1022882202305
Issue Date:
DOI: https://doi.org/10.1023/A:1022882202305